In the warning letters, the FDA denied the companies’ claims that the products can be classified as dietary supplements, citing the Investigational New Drug Applications submitted for CBD-containing pharmaceutical drug candidates Sativex and Epidiolex.
Sounds like they likely consider this as active ingredients?
News 
Market Data 
Discover 
